NCT06793215: An ongoing trial by Hoffmann-La Roche
This trial is ongoing. It must report results 3 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06793215 |
|---|---|
| Title | A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 24, 2025 |
| Completion date | Nov. 30, 2028 |
| Required reporting date | Nov. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |